Author:
Evens Andrew M.,Connors Joseph M.,Younes Anas,Ansell Stephen M.,Kim Won Seog,Radford John,Feldman Tatyana,Tuscano Joseph,Savage Kerry J.,Oki Yasuhiro,Grigg Andrew,Pocock Christopher,Dlugosz-Danecka Monika,Fenton Keenan,Forero-Torres Andres,Liu Rachael,Jolin Hina,Gautam Ashish,Gallamini Andrea
Abstract
Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma (cHL). We report results for older patients with cHL treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Modified progression-free survival (PFS) per independent review facility (IRF) for older versus younger patients (aged ≥60 versus
Publisher
Ferrata Storti Foundation (Haematologica)
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献